Romo Tammy sold (to issuer) $86K of THC

Romo Tammy sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Romo Tammy
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides ownership-change information only; it does not include new company fundamentals or external catalysts.

02

Market read

Traders may monitor for sentiment effects, but the filing lacks fundamental drivers, making it more of a positioning/flow datapoint than a catalyst.

03

What to watch

Code D (sale to issuer) and absence of a 10b5-1 plan detail suggest the transaction may be mechanical; without additional context, directional inference is weak.

Relevance 6/10Timing: Disclosure filed 2026-05-26 for a 2026-05-22 transaction; any market read-through would be short-lived.

Background

The article is an SEC Form 4 insider transaction filing for Tenet Healthcare director Romo Tammy.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Romo Tammy sold 493 shares to the issuer for $85,673.54 at $173.78/share, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price move; any reaction is likely brief and sentiment-neutral.

Evidence & confidence

The filing is a routine insider transaction disclosure, with no earnings/guidance, deal, regulatory, or litigation information provided.

Market effects

Minimal; insider Form 4s without fundamental updates rarely change sector risk pricing.

None indicated; transaction is company-specific and not tied to broader regional developments.

None indicated; no international or cross-border catalyst mentioned.

Counterpoint

If investors treat any insider selling as a signal, THC could see short-term negative sentiment despite the sale-to-issuer code D.

Key entities

  • Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold shares to the issuer (code D).

  • Romo Tammy

    Director who sold 493 shares to the issuer on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.